Haldun Muderrisoglu

Haldun Muderrisoglu

Auto-generated profile, based on publicly available information

Haldun Muderrisoglu

Department of Cardiology, Baskent University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
SES. Eroglu
S. Eroglu
LSL.E. Sade
L.E. Sade
AYA. Yildirir
A. Yildirir
UBU. Bal
U. Bal
SOS. Ozbicer
S. Ozbicer
HMH. Muderrisoglu
H. Muderrisoglu

1 January 2015 in World Journal of Diabetes
Verified
Journal Article
Open access
ABAkif Serhat Balcioglu
Akif Serhat Balcioglu
HMHaldun Müderrisoğlu
Haldun Müderrisoğlu
Cardiac autonomic neuropathy (CAN) is a frequent chronic complication of diabetes mellitus with potentially life-threatening outcomes. CAN is caused by the impairment of the autonomic nerve fibers regulating heart rate, cardiac output, myocardial contractility, cardiac electrophysiology and blood vessel constriction and dilatation. It causes a wide range of cardiac disorders, including resting tachycardia, arrhythmias, intraoperative cardiovascular instability, asymptomatic myocardial ischemia and infarction and increased rate of mortality after myocardial infarction. Etiological factors associated with autonomic neuropathy include insufficient glycemic control, a longer period since the onset of diabetes, increased age, female sex and greater body mass index. The most commonly used methods for the diagnosis of CAN are based upon the assessment of heart rate variability (the physiological variation in the time interval between heartbeats), as it is one of the first findings in both clinically asymptomatic and symptomatic patients. Clinical symptoms associated with CAN generally occur late in the disease process and include early fatigue and exhaustion during exercise, orthostatic hypotension, dizziness, presyncope and syncope. Treatment is based on early diagnosis, life style changes, optimization of glycemic control and management of cardiovascular risk factors. Medical therapies, including aldose reductase inhibitors, angiotensin-converting enzyme inhibitors, prostoglandin analogs and alpha-lipoic acid, have been found to be effective in randomized controlled trials. The following article includes the epidemiology, clinical findings and cardiovascular consequences, diagnosis, and approaches to prevention and treatment of CAN.

1 June 2009 in Atherosclerosis
Verified
Journal Article
Closed access
LSLeyla Elif Sade
Leyla Elif Sade
SESerpil Eroglu
Serpil Eroglu
HBHüseyin Bozbaş
Hüseyin Bozbaş
SÖSüleyman Özbiçer
Süleyman Özbiçer
MHMutlu Hayran
Mutlu Hayran
HMHaldun Müderrisoğlu
Haldun Müderrisoğlu

1 February 2006 in Atherosclerosis
Verified
Journal Article
Closed access
DEDogan Erdogan
Dogan Erdogan
HGHakan Gullu
Hakan Gullu
EYErkan Yildirim
Erkan Yildirim
DTDerya Tok
Derya Tok
IKIsmail Kirbas
Ismail Kirbas
HMHaldun Muderrisoglu
Haldun Muderrisoglu

11 September 2005 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
DED. Erdogan
D. Erdogan
HGH. Gullu
H. Gullu
MCM. Caliskan
M. Caliskan
EYE. Yildirim
E. Yildirim
MBM. Bilgi
M. Bilgi
HMH. Muderrisoglu
H. Muderrisoglu
Although uric acid (UA) is considered as an antioxidant, the relationship between serum UA levels and cardiovascular diseases is not clear yet. Higher brachial artery resting diameter (BD), impaired brachial artery flow-mediated dilatation (FMD), increased carotid intima-media thickness (IMT), decreased aortic distensibility (AoD), and increased aortic stiffness index (AoSI) and elastic modulus (AoEM) are predictors for development and/or progression of atherosclerosis. In this study, BD, FMD, carotid IMT, AoD, AoSI and AoEM were studied in healthy subjects with UA concentrations in physiological range. One hundred 24 healthy volunteers between 26 and 55 years of age were included in this study. Each subject had a serum UA levels in normal range. Carotid IMT, BD and brachial FMD were measured by means of high-resolution vascular ultrasound. AoD, AoSI, AoEM were examined by transthoracic echocardiography. Endothelium-dependent dilatation (EDD) was assessed by establishing reactive hyperemia and endothelium-independent dilatation (EID) was determined by using sublingual isosorbide dinitrate. Although carotid IMT and EDD were significantly correlated with UA concentrations (r = 0.346, p < 0.0001; r = −0.255, p < 0.05, respectively), EID measurements were not significantly correlated with serum UA concentrations (r = − 0.105, p > 0.05). In addition, AoSI and AoEM were significantly correlated with serum UA levels (r = 0.368, p < 0.0001; r = −0.366, p < 0.0001, respectively), and there was a significant inverse correlation between AoD and serum UA concentrations (r = −0.366, p < 0.0001). Furthermore, in multivariate analysis, we found that serum UA concentrations were correlated with increased carotid IMT, reduced FMD and increased aortic stiffness independent of other cardiovascular risk factor (β = 256, p = 0.002; β = −193, p = 0.03; β = 0.295, p < 0.0001, respectively). In healthy subjects, increased serum UA concentrations, even in physiological range, are a risk factor for increased carotid IMT, reduced FMD and increased aortic stiffness independent of other cardiovascular risk factor, and other factors related to the metabolic syndrome.

6 February 2007 in Circulation
Verified
Journal Article
Open access
PDF file
DEDogan Erdogan
Dogan Erdogan
IYIbrahim Yildirim
Ibrahim Yildirim
OCOzgur Ciftci
Ozgur Ciftci
IOIsmail Ozer
Ismail Ozer
MCMustafa Caliskan
Mustafa Caliskan
HMHaldun Muderrisoglu
Haldun Muderrisoglu
Background— The assessment of coronary flow reserve (CFR) by transthoracic Doppler echocardiography has recently been introduced into clinical practice, and reduced CFR has been suggested to be a sensitive indicator of hypertensive end-organ damage; however, to date, this methodology has not been used to evaluate CFR in subjects with prehypertension. Accordingly, the present study was designed to evaluate CFR in subjects with prehypertension. Methods and Results— We measured CFR of 40 subjects with prehypertension, 60 patients with hypertension, and 50 normotensive healthy volunteers using transthoracic Doppler echocardiography. None of the subjects had any systemic disease. Age, gender, body mass index, heart rate, lipid profiles, fasting glucose levels, and hemoglobin were similar among the 3 groups. CFR was significantly lower in the hypertension group than in the prehypertension and control groups; in addition, it was significantly lower in subjects with prehypertension than in control subjects (2.23±0.47, 2.54±0.48, and 2.91±0.53, respectively). Furthermore, we found that prehypertension (β=−0.31, P <0.01) and hypertension (β=−0.57, P <0.01) were significant predictors of lower CFR in a multivariable model that adjusted for other variables. CFR was significantly and inversely correlated with age ( r =−0.20, P =0.01), systolic blood pressure ( r =−0.51, P <0.01), diastolic blood pressure ( r =−0.47, P <0.01), high-sensitivity C-reactive protein levels ( r =−0.21, P =0.01), left atrium diameter ( r =−0.22, P <0.01), mitral E deceleration time ( r =−0.19, P =0.02), and mitral A velocity ( r =−0.27, P <0.01), whereas mitral E/A ratio was significantly and positively correlated with CFR ( r =0.26, P <0.01). Conclusions— CFR is impaired in subjects with prehypertension, but this impairment is not as severe as that in hypertension.